Wern­er Cautreels is leav­ing Se­lec­ta, hand­ing reins to Bay­er vet; No­var­tis lines up a man­u­fac­tur­ing part­ner for Chi­na CAR-T mar­ket­ing

→ Wern­er Cautreels, the long­time CEO at Se­lec­ta Bio­sciences $SELB, is re­tir­ing from his post. The biotech re­port­ed this morn­ing that Bay­er vet Carsten Brunn has been named as the new CEO. Cautreels is stay­ing on as an ad­vis­er af­ter he leaves his job at the end of this year. Se­lec­ta is prep­ping a Phase III study for SEL-212, an ex­per­i­men­tal gout drug. Cautreels was named CEO in 2010, a cou­ple of years af­ter the launch of the com­pa­ny fo­cused on Syn­thet­ic Vac­cine Par­ti­cle tech from the lab of MIT’s Bob Langer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER